A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

CNBC's Karen Gilchrist discusses Wegovy-maker Novo Nordisk's efforts to regain U.S. market share amid increased competition ...

Wegovy is designed to be taken once a week by self-injection. Patients start on the lowest dose, 0.25 milligrams, and move up to the maintenance dose, 2.4 milligrams, over the course of 16 weeks.

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...